SpinalCyte receives notice of acceptance on Australian patent for spinal disc tissue engineering


SpinalCyte, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts, announced on 16 December that the Australian Patent Office issued a notice of acceptance on its patent application “Methods and compositions for repair of cartilage using an in vivo bioreactor” to regrow the spinal disc, using human dermal fibroblasts. 

The allowed claims include the use of human dermal fibroblasts from the patient’s own body, to regrow the nucleus of the spinal disc in vivo. The cell-based therapy uses the dermal cells to differentiate into cartilage type cells necessary to regrow the nucleus pulposus.

“This is another major milestone and gives us additional international protection for our position as a leader in this emerging technology,” said Pete O’Heeron, SpinalCyte’s CEO. “This is our first Australian Patent and we are excited the Australian patent Office has validated the uniqueness of our cell-based technology to repair the disc.”

SpinalCyte received the US Patent Office registration and Chinese Patent Office registration in July 2011.